HTG Molecular Diagnostics Balance Sheet Health
Financial Health criteria checks 0/6
Insufficient data to determine the health of HTG Molecular Diagnostics
Key information
n/a
Debt to equity ratio
n/a
Debt
| Interest coverage ratio | n/a |
| Cash | n/a |
| Equity | n/a |
| Total liabilities | n/a |
| Total assets | n/a |
Recent financial health updates
Recent updates
HTG Molecular Q2 GAAP loss per share widens, revenue down
Aug 11HTG Molecular Diagnostics amends senior loan facility
Jul 18Is HTG Molecular Diagnostics (NASDAQ:HTGM) Using Debt In A Risky Way?
Dec 10
Is HTG Molecular Diagnostics (NASDAQ:HTGM) Weighed On By Its Debt Load?
Aug 27HTG Molecular completes product design lock for planned transcriptome panel
Jun 14These Analysts Think HTG Molecular Diagnostics, Inc.'s (NASDAQ:HTGM) Sales Are Under Threat
Mar 26What Type Of Returns Would HTG Molecular Diagnostics'(NASDAQ:HTGM) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?
Jan 20
HTG shares surge after upbeat 2020 revenue forecast
Jan 05HTG Molecular Diagnostics announced 1:15 reverse stock split
Nov 23HTG Molecular Diagnostics (HTGM) Investor Presentation - Slideshow
Nov 18Financial Position Analysis
Short Term Liabilities: Insufficient data to determine if HTGM.Q's short term assets cover its short term liabilities.
Long Term Liabilities: Insufficient data to determine if HTGM.Q's short term assets cover its long term liabilities.
Debt to Equity History and Analysis
Debt Level: Insufficient data to calculate HTGM.Q's net debt to equity ratio to determine if it is satisfactory.
Reducing Debt: Insufficient data to determine if HTGM.Q's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: Insufficient data to determine if HTGM.Q's debt is well covered by operating cash flow.
Interest Coverage: Insufficient data to determine if HTGM.Q's interest payments on its debt are well covered by EBIT.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/29 03:25 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2023/03/31 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
HTG Molecular Diagnostics, Inc. is covered by 6 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mark Massaro | Canaccord Genuity |
| Kristen Kluska | Cantor Fitzgerald & Co. |
| Alexander Nowak | Craig-Hallum Capital Group LLC |